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ABSTRACT 
Objective: The prime objective of the current work is to develop a simple, rapid, efficient, economical and stability indicating LC-MS 
(liquid chromatography–mass spectroscopy) compatible RP - HPLC (reverse phase – high performance liquid chromatography) 
method for the analysis of emtricitabine (EMT), tenofovir disoproxil fumarate (TDF), cobicistat (COB) and elvitegravir (ELV) in bulk, 
marketed formulation (Stribild) and in In-vitro dissolution method.  
Method: The chromatography was achieved on Unisol C18 column (250 × 4.0 mm, 3 µ) with a mobile phase combination of acetate 
buffer (adjusted with dilute glacial acetic acid to pH 4) and acetonitrile in gradient mode at a flow rate of 1mL/min and the detection 
was performed at 260 nm using PDA (photo diode array) detector. Forced degradation studies were performed and the % 
degradation under various stress conditions was calculated. The developed RP-HPLC method was applied for Stribild tablets to 
study the dissolution profile.  
Results: The retention times for emtricitabine, tenofovir disoproxil fumarate, cobicistat and elvitegravir were 5.7, 12.1, 16.3 and 
19.4 min respectively. The % degradation was below 20% which is within the limits. The percent drug release was found to meet 
USP specification, i.e. not less than 80% of amount of labeled drug EMT, TDF, COB and ELV dissolved in 30min.  
Conclusion: The method was validated as per ICH guidelines and all the validation parameters were within the compendial 
requirements. The proposed method can be successfully adopted for the analysis of Stribild tablets in pharmaceutical industries. 
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1. INTRODUCTION  
The human immunodeficiency virus (HIV) is a lentivirus (a 
sub group of retroviruses) that causes HIV infection and 
over time acquired immunodeficiency syndrome (AIDS). 
AIDS is a condition in humans in which progressive failure 
of the immune system allows life-threatening infections 
and cancers. STRIBILD, the first integrase inhibitor- based 
single tablet regimen containing emtricitabine (EMT), 
tenofovir disoproxil fumarate (TDF), cobicistat (COB) and 
elvitegravir (ELV) for HIV-1 infection, meets current WHO 
treatment guidelines for a complete fixed-dose, once daily 
highly active antiretroviral therapy (HAART) regimens. 
HAART is the name given to aggressive treatment 
regimens used to suppress HIV viral replication and the 
progression of HIV disease. Stribild is a pill combination of 
four active ingredients-150 mg of Elvitegravir, 150 mg of 
Cobicistat, 200 mg of Emtricitabine and 300 mg of 
Tenofovir disoproxil fumarate (equivalent to 245 mg of 
Tenofovir Disoproxil) and is taken once a day 1-3 
Emtricitabine: The chemical name of Emtricitabine (EMT) 
is 6-(3-Chloro-2-fluorobenzyl)-1-[(2S)-1 hydroxy-3-methyl 
butan-2-yl]-7-methoxy-4-oxo-1, 4-dihydro quinoline-3-
carboxylic acid. Emtricitabine is the (-) enantiomer of a 
thio analog of cytidine, which differs from other cytidine 
analogs in that it has a fluorine in the 5-position. 
Emtricitabine is a nucleoside reverse transcriptase 
inhibitor (NRTI) for the treatment of HIV infection in 
adults. It has a molecular formula of C
8
H
10
FN
3
O
3 
S and a 
molecular weight of 247.25. It is a white to off-white 
crystalline powder with a solubility of approximately 112 
mg/mL in water at 25°C.  It has the following structural 
formula 
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Figure 1: Structure of Emtricitabine 
 
Tenofovir disoproxil fumarate: Tenofovir disoproxil 
fumarate (TDF) is a fumaric acid salt of the bis-isopropoxy 
carbonyl oxy methyl ester derivative of tenofovir. The 
chemical name of TDF is 9-[(R)-2- [[bis [[(isopropoxy 
carbonyl) oxy] methoxy] phosphinyl] methoxy] propyl] 
adenine fumarate. TDF belongs to a class of antiretroviral 
drugs known as nucleotide analogue reverse transcriptase 
inhibitors (NRTIs). It has a molecular formula of 
C
19
H
30
N
5
O
10
P • C
4
H
4
O
4 
and a molecular weight of 635.51. It 
is a white to off-white crystalline powder with a solubility 
of 13.4 mg/mL in water at 25 °C. It has the following 
structural formula 
 
Figure 2: Structure of Tenofovir disoproxil fumarate 
 
Cobicistat: The chemical name for Cobicistat (COB) is 1, 3-
Thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2- [(methyl {[2-
(propan-2-yl)-1,3-thiazol-4-yl] methyl} carbamoyl) amino] 
-4 (morpholin-4-yl) butanol] amino}-1,6-diphenyl hexan-2-
yl] carbamate. Cobicistat acts as an HIV integrase inhibitor. 
Cobicistat is the only other booster approved for use as a 
part of HAART, Cobicistat has no anti-HIV activity of its 
own. Cobicistat is a potent inhibitor of cytochrome P450 
3A enzymes, including the important CYP3A4 subtype. It 
also inhibits intestinal transport proteins, increasing the 
overall absorption of several HIV medications. It has a 
molecular formula of C
40
H
53
N
7
O
5
S
2 
and a molecular weight 
of 776.0. It is adsorbed onto silicon dioxide. Cobicistat on 
silicon dioxide is a white to pale yellow solid with a 
solubility of 0.1 mg/mL in water at 20 °C.  It has the 
following structural formula 
 
Figure 3: Structure of Cobicistat 
Elvitegravir: The chemical name of Elvitegravir (ELV) is 6- 
(3-Chloro-2-fluorobenzyl) - 1- [(2S)-1hydroxy-3-methyl 
butan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-
carboxylic acid. Elvitegravir is a drug used for the 
treatment of HIV infection. It acts as an integrase inhibitor. 
It has a molecular formula of C
23
H
23
Cl F NO
5 
and a 
molecular weight of 447.9. Elvitegravir is a white to pale 
yellow powder with a solubility of less than 0.3 µg/mL in 
water at 20 °C. It has the following structural formula 
 
Figure 4: Structure of Elvitegravir 
 
Objective  
Literature survey reveals that there are very few RP - HPLC 
methods available for the estimation of EMT, TDF, COB and 
ELV individually, but with very poor resolution between 
the retention time of the four drugs and the degradation 
products obtained in the forced degradation studies and 
there is no dissolution method reported till to date for this 
quad pill. Hence there is a need to develop and validate a 
new LC-MS compatible stability indicating RP-HPLC 
method for developing assay and dissolution methods for 
the marketed formulation Stribild 4-12 
2. METHODS  
2.1 Apparatus: 
An Agilent Infinity 1260 HPLC system equipped with 
quaternary pumps G1311C, Degasser G4225A, Auto 
sampler G1329B, Thermostatted column compartment 
G1316A with PDA detector G4212B was used. The 
software used for data acquisition was Open LAB CDS EZ 
Chrom A.04.05. Lab India D5 8000 Dissolution test 
apparatus, Mettler Toledo ME 204 weighing balance, 
Magnetic stirrer, Kemi Hot air oven, Eutech 700 pH meter, 
Double distillation apparatus.  
2.2 Chemicals: 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat, 
Elvitegravir working standards and Stribild tablets were 
kindly given as gift samples by Aurobindo Pharma Limited, 
Hyderabad. HPLC grade solvents include acetonitrile, 
water and methanol. Analytical grade chemicals include 
ammonium acetate, sodium hydroxide, hydrochloric acid, 
30% hydrogen peroxide, ortho phosphoric acid, glacial 
acetic acid and potassium dihydrogen phosphate, tween 80 
were purchased from E. Merck Limited, Mumbai, India.  
2.3 Assay Method  
2.3.1 Selection of Detection Wavelength: 
Drug solutions of 10 μg/mL were prepared for the four API 
working standards individually and scanned over the 
range of 200-400 nm in UV/VIS Spectrophotometer using 
methanol as blank. The λ max of Emtricitabine, Tenofovir 
disoproxil fumarate, Cobicistat and Elvitegravir were found 
at 283 nm, 259 nm, 240 nm and 258 nm respectively. The 
optimum wavelength was selected based on isosbestic 
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point at 260 nm which represents the wavelength where 
the sample solution (Stribild) has an absorption maximum. 
Higher wavelength also helps in reducing interferences 
from common excipients used in the formulation. 
2.3.2 Preparation of Buffer: 
Accurately weighed 1.54 g of ammonium acetate and 
dissolved in 1000 mL of water. The pH was adjusted to 4.0 
with 30% glacial acetic acid and filtered through 0.45 µ 
nylon filter and degassed. 
2.3.3 Preparation of Diluent: 
Diluent-1: HPLC grade methanol was used as 1st diluent. 
Diluent-2: The second diluent was prepared by using a 
mixture of methanol: buffer in the ratio 60: 40. 
2.3.4 Preparation of Blank: 
The diluent-2 prepared by using a mixture of methanol: 
buffer in the ratio 60: 40, was injected as blank solution.  
3.3.5 Preparation of Placebo Solution: 
300 mg of placebo was weighed and transferred to 50 mL 
volumetric flask to which 30 mL of diluent-1 was added 
and sonicated for 15min at room temperature and made 
up to final volume to prepare stock solution. The stock 
solution was filtered through 0.45 μ nylon filter and 3 mL 
of filtered solution was transferred to 50 mL volumetric 
flask and made up to final volume with diluent-2. 
 
2.3.6 Preparation of Working Standard Solution: 
Accurately weighed and transferred about 20 mg of 
Emtricitabine, 30 mg of Tenofovir disoproxil fumarate, 15 
mg of Cobicistat and 15 mg of Elvitegravir working 
standards into a 10 mL clean and dry volumetric flask and 
5 mL of methanol was added and sonicated for 10 min to 
dissolve. The final volume was made up with methanol and 
filtered through 0.45 µ nylon filter. 1 mL from the above 
filtered stock solution was taken and made up to 10 mL 
with diluent-2. The final concentrations of EMT, TDF, COB 
and ELV were about 200 ppm, 300 ppm, 150 ppm and 150 
ppm respectively.  
2.3.7 Preparation of Sample Solution: 
Ten tablets were weighed and average weight was 
calculated. The tablets were crushed with a mortar and 
pestle. A portion of powder equivalent to the weight of one 
tablet was accurately weighed and transferred to a 100 mL 
volumetric flask. Approximately 50 mL methanol was 
added and the mixture was sonicated for 15min with 
intermittent shaking, then 20 mL of water was added and 
sonicated for 30 min. The contents were restored to room 
temperature and diluted to final volume with methanol to 
furnish stock solution. The stock solution was filtered 
through 0.45 μ nylon filter and 10 mL of the filtered 
solution was transferred to a 50 mL volumetric flask and 
made up to volume with diluent-2. The final concentrations 
of EMT, TDF, COB and ELV were about 200 ppm, 300 ppm, 
150 ppm and 150 ppm respectively. The optimized 
chromatographic conditions are mentioned in table 1. 
 
Table 1: Optimized Chromatographic Conditions 
Parameter Optimized conditions 
Stationary phase (column) Unisol C18 column (250 mm × 4.0 mm, 3 µ) 
Mobile phase Acetate buffer and acetonitrile in gradient mode 
Time 
(min) 
Buffer 
(% v/v) 
Acetonitrile 
(% v/v) 
0.01 90 10 
5 60 40 
10 50 50 
13 40 60 
15 20 80 
20 10 90 
23 50 50 
28 90 10 
 
Flow rate 1 mL/min 
Injection volume 15 µL 
Column temperature 30°C 
Detection  Performed at 260 nm using PDA detector 
Run time 30 min 
 
2.4 Validation of the Developed Method 
The developed and optimized RP-HPLC method was 
validated according to international conference on 
harmonization (ICH) guidelines Q2(R1) in order to 
determine the system suitability, linearity, limit of 
detection (LOD), limit of quantification (LOQ), precision, 
accuracy, ruggedness and robustness. 
2.5 Forced Degradation Studies 
2.5.1 Acid degradation: 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir working standard solutions (1mg/mL) 
were individually treated with 5mL of 0.1N HCl at room 
temperature for 24 hours and then neutralized with 0.1N 
NaOH. The solutions were further diluted to required 
concentrations with diluent-2. 
2.5.2 Alkali degradation: 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir working standard solutions (1mg/mL) 
were individually treated with 5mL of 0.1N NaOH at room 
temperature for 24 hours and then neutralized with 0.1N 
HCl. The solutions were further diluted to required 
concentrations with diluent-2.  
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2.5.3 Oxidative degradation: 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir working standard solutions (1mg/mL) 
were individually treated with 30% H2O2 at room 
temperature for 24 hours. The solutions were further 
diluted to required concentrations with diluent-2.  
2.5.4 Thermal degradation: 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir working standards of 10mg were taken 
individually into petri dishes and kept in a hot air oven at 
70° C for 24 hours. The stock solutions were prepared with 
diluent-1 and further diluted to required concentrations 
with diluent-2. 
3.5.5 Photolytic degradation: 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir working standard solutions (1mg/mL) 
were prepared individually, and exposed to sunlight for 
8hours on three consecutive days. Then they were further 
diluted to required concentrations with diluent-2.  
2.6 Dissolution Method:  
Application of developed RP-HPLC method for the 
dissolution studies of Stribild tablets.  
2.6.1 Preparation of Dissolution Medium (2.0% 
polysorbate 80 in 0.01N HCl): 
20g of polysorbate 80 was transferred to 1000mL of 0.01N 
HCl and mixed. 
2.6.2 Dissolution parameters: 
Medium: 0.1 N Hydrochloric acid 
Volume: 1000 mL 
Apparatus: USP Apparatus-II (paddle) with stainless steel 
helical sinkers 
RPM: 100 rpm 
Temperature: 37.0° ± 0.5°C 
Time: 10, 20, 30, 40, 50 and 60 minutes  
2.6.3 Preparation of Working Standard Solution: 
Refer to preparation of working standard solution in assay 
method-3.3.6.  
2.6.4 Preparation of Sample Solution: 
The parameters of dissolution apparatus were set as 
mentioned above. One Stribild tablet was placed into each 
of the six dissolution vessels, one vessel with dissolution 
medium without sample and the dissolution test was 
performed. At the specified time intervals, 10 mL of the 
sample solution was withdrawn from each dissolution 
vessel. The solution was filtered through 0.45 µ membrane 
filter. 10 mL of fresh dissolution medium maintained at 
37.0°C ± 0.5°C was replaced after every time point 
sampling. 5 mL of this solution was transferred to 20 mL 
volumetric flask and diluted to volume with dissolution 
medium and mixed. 
2.6.5 Procedure:  
The same procedure and the optimized chromatographic 
conditions (refer table-1) developed for assay method was 
also applicable for dissolution method. The system 
suitability was evaluated by injecting 10 µL of working 
standard solution five times into the chromatograph. Then 
blank (dissolution medium), working standard and 
samples from six dissolution vessels collected at each 
specified time interval were made up to final concentration 
and injected into the chromatograph, the chromatograms 
were recorded and peak areas were measured. The amount 
of Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir dissolved in dissolution medium at specific 
time intervals were calculated and the dissolution profile 
was studied.  
3. RESULTS AND DISCUSSION 
In order to achieve good resolution between all the four 
drugs, different buffers with pH-conditions such as 
phosphate buffer at pH 3.0 and trifluoro acetic acid and 
different proportions of solvents like methanol and 
acetonitrile were tested. However, in acetate buffer 
(adjusted with dilute glacial acetic acid to pH 4) and 
acetonitrile in gradient mode achieved good satisfactory 
results at a flow rate of 1.0 mL/min. The retention times of 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir were found to be 5.7, 12.1, 16.3 and 19.4 
min respectively. The chromatograms of blank, placebo, 
working standards of Emtricitabine, Tenofovir disoproxil 
fumarate, Cobicistat, Elvitegravir, four standard API’s 
mixture and Stribild sample solution were shown in figures 
1 to 8. 
 
 
Figure 1: Chromatogram of Blank 
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Figure 2: Chromatogram of Placebo 
 
Figure 3: Chromatogram of Emtricitabine working standard 
 
 
Figure 4: Chromatogram of Tenofovir disoproxil fumarate working standard 
 
Figure 5: Chromatogram of Cobicistat working standard 
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Figure 6: Chromatogram of Elvitegravir working standard 
 
Figure 7: Chromatogram of four Standard API’s mixture 
 
Figure 8: Chromatogram of Stribild sample 
 
4.1 Assay: 
Analysis of Stribild tablets was performed by the proposed 
method and the percent assay of the formulation was 
calculated in triplicate. The assay percentage of 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir were found to be within limits in the 
sample Stribild tablets and the results are shown in table 2.  
 
Table 2: Assay results of Stribild tablets 
S.NO. Drug name Label claim (mg) Amount found(mg) Assay (%) * 
1 Emtricitabine 200 199.2 99.6 
2 Tenofovir 300 297.5 99.2 
3 Cobicistat 150 148.7 99.1 
4 Elvitegravir 150 150.8 100.5 
 * = Average assay% of 3 replicate injections  
 
4.2 Method Validation:  
4.2.1 System suitability: 
10µL of standard solution was injected five times into the 
chromatograph, the chromatograms were recorded and 
the peak areas were measured. The column efficiency for 
EMT, TDF, COB and ELV peaks should not be less than 
5000 plate counts and tailing factor should be between 
0.80 to 2.0. RSD for peak areas from five replicate 
injections should not be more than 2.0%. Parameters such 
as number of theoretical plates, average area and peak 
tailing were determined and all the parameters were 
within the limits. Results are shown in table 3. 
mAU 
m
AU 
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Table 3: System suitability data 
Parameters EMT TDF COB ELV 
Theoretical plates* 47155 10206 15700 25735 
Tailing factor* 0.9 1.2 0.8 1.3 
Average peak area* 185376024 169302341 8113118 624388448 
Standard deviation 843249.78 554654.95 51989.9 5236220 
% RSD  0.45 0.33 0.64 0.84 
* = Average result of 6 replicate injections 
 
4.2.2 Specificity: 
The specificity of the analytical method was established by 
injecting the 100 μg/mL concentration solutions of diluent 
(blank), placebo, working standards and sample solution 
individually to investigate interference from the 
representative peaks. From the obtained chromatograms 
in figures 1 to 8 it can be inferred that there were no co-
eluting peaks at the retention time of EMT, TDF, COB and 
ELV, which shows that peak of analyte was pure and the 
excipients in the formulation did not interfere with the 
analyte of interest.  
4.2.3 Linearity:  
Linearity was evaluated by analyzing different 
concentrations of the standard solutions of Emtricitabine, 
Tenofovir disoproxil fumarate, Cobicistat and Elvitegravir 
solutions. 6 working standard solutions ranging between 
25-150, 37.5-225, 18.75-112.5 and 18.75-112.5 μg/mL 
were prepared and injected (n = 3). The response was a 
linear function of concentration over peak area and were 
subjected to linear least-squares regression analysis to 
calculate the calibration equation and correlation 
coefficient, the calibration curves are shown in figures 9 to 
12.
 
  
        
Figure 9: Calibration curve for EMT                         Figure 10: Calibration curve for TDF 
 
          
Figure 11: Calibration curve for COB                                Figure 12: Calibration curve for ELV 
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Elvitegravir 
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4.2.4 Limit of detection and limit of quantification:   
Limit of detection (LOD) and limit of quantification (LOD) 
of Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir were determined by calibration curve 
method. Solutions of EMT, TDF, COB and ELV were 
prepared in linearity range and injected (n = 3). Average 
peak areas were plotted against concentration. These were 
calculated by using following equations (ICH, Q2 (R1)). The 
LOD and LOQ values are reported in table 4. 
LOD = 3.3 × σ/S and LOQ = 10 × σ/S  
Where σ = the standard deviation of the response and S = 
slope of the calibration curve. 
4.2.5 Precision:  
Repeatability/method precision was determined in 
accordance with ICH guidelines. Six replicate injections 
(n=6) of same concentration (100 μg/mL) were analyzed. 
Determinations were performed on the same day as well as 
on consequent days (reproducibility/ruggedness). % RSD 
for Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir were found to be within acceptable limit of 
≤ 2. Hence the method is precise, reproducible and rugged 
for 48 hours study and the results are summarized in table 
5 and 6. 
Table 4: LOD and LOQ data 
Drug name LOD (μg/mL) LOQ (μg/mL) 
EMT 0.92 2.78 
TDF 1.04 3.14 
COB 0.66 2.01 
ELV 0.37 1.12 
 
 
  
Table 5: Method Precision (repeatability) data for EMT, TDF, COB and ELV 
Repeatability (Peak Areas) 
S. NO. EMT TDF COB ELV 
1 185374024 169302345 8102589 624389254 
2 184956826 169123548 8154265 628975425 
3 184685792 168548781 8078251 629457821 
4 185168745 168745985 8054654 619658724 
5 184142589 169974623 8169824 618957214 
6 184298745 167489524 8015786 627854625 
Mean 184771120.2 168864129.3 8095894.8 624882177.2 
SD 486118.4 836120.6 58901.5 4672456.8 
% RSD 0.26 0.49 0.72 0.74 
 
Table 6: Intraday and Inter-day Precision data for EMT, TDF, COB and ELV 
Drug name Time interval % Assay * Statistical parameters  
EMT 0hrs 
8hrs 
Day 1 
Day 2 
101.4 
101.7 
101.4 
101.6 
Mean = 101.5 
SD = 0.15 
%RSD = 0.15 
TDF 0hrs 
8hrs 
Day 1 
Day 2 
100.7 
100.2 
101.1 
101.6 
Mean = 100.9 
SD = 0.59 
%RSD = 0.59 
COB 0hrs 
8hrs 
Day 1 
Day 2 
101.4 
100.6 
100.5 
101.2 
Mean = 100.9 
SD = 0.44 
%RSD = 0.44 
ELV 0hrs 
8hrs 
Day 1 
Day 2 
101.6 
101.3 
100.8 
101.4 
Mean = 101.3 
SD = 0.34 
%RSD = 0.34 
* = Average assay of 6 replicate injections 
 
4.2.6 Accuracy:  
To the placebo solution, known amounts of standard 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir corresponding to 50, 100 and 150% of 
target concentrations were added. Mean recovery (%) for 
EMT, TDF, COB and ELV are 98.97, 99.99, 100.20 and 
100.17 respectively and these results are within acceptable 
limit of 98-102 %. The % RSD for EMT, TDF, COB and ELV 
are 0.5, 0.9, 0.7 and 0.8 respectively and these results were 
within limit of ≤ 2. Hence the proposed method is accurate 
and the results are summarized in table 7. 
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Table 7:  Results of Accuracy for EMT, TDF, COB and ELV 
Drug 
name 
Conc. 
(%) 
Amount 
taken* 
(μg/mL) 
Amount 
spiked* 
(μg/mL) 
Amount 
recovered* 
(μg/mL) 
% recovery * Statistical 
parameters 
 
EMT 
50 
100 
150 
30 
30 
30 
15 
30 
45 
45.2 
59.5 
75.6 
100.4 
99.2 
100.8 
Mean %: 100.1 
SD: 0.83 
%RSD: 0.83 
 
TDF 
50 
100 
150 
50 
50 
50 
25 
50 
75 
74.8 
100.6 
125.9 
99.7 
100.6 
100.7 
Mean %: 100.3 
SD: 0.55 
%RSD: 0.55 
 
COB 
50 
100 
150 
20 
20 
20 
10 
20 
30 
30.2 
39.6 
50.4 
100.6 
99 
100.8 
Mean %: 100.1 
SD: 0.99 
%RSD: 0.98 
 
ELV 
50 
100 
150 
20 
20 
20 
10 
20 
30 
30.3 
40.6 
50.4 
101 
101.5 
100.8 
Mean %: 101.1 
SD: 0.36 
%RSD: 0.36 
* = Average result of 3 replicate injections 
 
4.2.7 Robustness:  
The method remained unaffected by deliberate small 
changes in parameters like flow rate and column 
temperature. Below tabulated % RSD values of % assays 
and retention times were within the tolerance limits and 
indicate that the method is robust. The results are reported 
in table 8. 
  
Table 8: Robustness study results of EMT, TDF, COB and ELV 
Drug name Parameter Change 
in ratio 
%Assay * 
 
Statistical parameters 
EMT 
 
Flow rate 
 
 
0.9 mL 
1.0 mL 
1.1 mL 
99.8 
100.6 
100.9 
Mean %: 100.5 
SD: 0.51 
% RSD: 0.51 
Column 
temperature 
28 °C 
30 °C 
32 °C 
100.5 
100.2 
100.8 
Mean %: 100.5 
SD: 0.3 
% RSD: 0.29 
TDF 
 
Flow rate 
 
 
0.9 mL 
1.0 mL 
1.1 mL 
100.6 
100.4 
101.5 
Mean %: 100.8 
SD: 0.58 
% RSD: 0.58 
Column temperature 28 °C 
30 °C 
32 °C 
100.6 
100.4 
100.7 
Mean %: 100.6 
SD: 0.15 
% RSD: 0.15 
COB 
 
Flow rate 
 
 
0.9 mL 
1.0 mL 
1.1 mL 
99.5 
100.2 
100.6 
Mean %: 100.1 
SD: 0.56 
%RSD: 0.56 
Column temperature 28 °C 
30 °C 
32 °C 
100.8 
101.6 
101.3 
Mean %: 101.2 
SD: 0.40 
%RSD: 0.40 
ELV 
 
Flow rate 
 
 
0.9 mL 
1.0 mL 
1.1 mL 
100.7 
101.6 
101.9 
Mean %: 101.4 
SD: 0.62 
%RSD: 0.62 
Column temperature 28 °C 
30 °C 
32 °C 
100.7 
100.5 
100.8 
Mean %: 100.7 
SD: 0.15 
%RSD: 0.15 
* = Average result of 3 replicate injections 
 
4.3 Forced Degradation Studies: 
For all the forced degradation samples, the purity angle 
formed was less than purity threshold, this indicates that 
there is no interference from degradants in quantitating 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir peaks in Stribild tablets. There was no 
purity flag observed and the % degradation was less than 
20%. Thus, this method is considered to be “stability 
indicating”. The results are reported in table 9. The 
chromatograms of drugs which showed specific 
degradation peaks which are well separated from the main 
drug peak with good resolution after forced degradation 
studies are reported in figures 13 to 18. 
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Table 9: Forced degradation studies at different stress conditions 
Stress Condition % Degradation Purity Angle  Purity Threshold Pass/ Fail 
Emtricitabine 
Control --- 0.156 0.441 No 
Acid 3.4 0.132 0.330 No 
Alkali 16.8 0.144 0.341 No 
Oxidation 18.6 0.285 0.546 No 
Thermal 2.4 0.399 0.652 No 
Photostability 3.6 0.124 0.332 No 
Tenofovir disoproxil fumarate 
Control --- 0.186 0.541 No 
Acid 17.6 0.182 0.360 No 
Alkali 18.7 0.244 0.421 No 
Oxidation 3.1 0.212 0.584 No 
Thermal 2.3 0.412 0.674 No 
Photostability 2.8 0.184 0.392 No 
Cobicistat 
Control --- 0.136 0.481 No 
Acid 10.8 0.122 0.230 No 
Alkali 14.5 0.184 0.311 No 
Oxidation 9.6 0.285 0.546 No 
Thermal 9.8 0.364 0.782 No 
Photostability 10.3 0.224 0.432 No 
Elvitegravir 
Control --- 0.256 0.441 No 
Acid 13.2 0.232 0.338 No 
Alkali 1.2 0.274 0.461 No 
Oxidation 2.5 0.215 0.512 No 
Thermal 1.4 0.297 0.552 No 
Photostability 1.7 0.184 0.375 No 
 
       
Figure 13: Chromatogram of acid hydrolysis of Emtricitabine 
 
 
Figure 14: Chromatogram of alkali hydrolysis of Emtricitabine 
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Figure 15: Chromatogram of oxidation of Emtricitabine 
 
Figure 16: Chromatogram of acid hydrolysis of Tenofovir disoproxil fumarate 
 
Figure 17: Chromatogram of alkali hydrolysis of Tenofovir disoproxil fumarate 
 
Figure 18: Chromatogram of acid hydrolysis of Elvitegravir 
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4.4 Dissolution Method: 
The validated RP-HPLC method developed was successfully 
applied for the In-vitro dissolution method for analysis of 
Stribild tablets. The release rate of Emtricitabine, Tenofovir 
disoproxil fumarate, Cobicistat and Elvitegravir from 
immediate release Stribild tablets was determined using 
United State Pharmacopoeia dissolution testing apparatus 
II (paddle method). The percent drug release was found to 
meet USP specification, i.e. not less than 80% of amount of 
labeled drug EMT, TDF, COB and ELV dissolved in 30min.  
 
Figure 19: In-vitro dissolution profile of Stribild tablets 
There was no interference of blank with the standard and 
sample chromatograms. The In-vitro dissolution profile of 
cumulative percentage of drug released verses time is 
presented in figure 19. 
4. CONCLUSION  
A simple and rugged LC-MS compatible RP-HPLC method 
has been described for simultaneous determination of 
Emtricitabine, Tenofovir disoproxil fumarate, Cobicistat 
and Elvitegravir in active pharmaceutical ingredients, assay 
for marketed formulation (Stribild) and to study the 
dissolution profile in Stribild tablets without any additional 
pretreatment. The proposed method was validated in 
accordance with ICH guidelines by testing its parameters 
which include system suitability, specificity, precision, 
linearity, LOD, LOQ, accuracy and robustness. The method 
was very specific to separate the peaks of active 
pharmaceutical ingredients from the degradation products 
which were obtained with good resolution and purity angle 
less than purity threshold showing peak purity of the four 
drugs after forced degradation studies. Thus, stress 
induced studies prove the effectiveness of the proposed 
stability indicating RP-HPLC method which can be adopted 
in routine analysis of Stribild tablets in pharmaceutical 
industries. 
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